BTSA1 is primarily utilized in research focused on cancer therapy, particularly in studies involving apoptosis, the process of programmed cell death. It functions as an inhibitor of the anti-apoptotic protein MCL-1, which is often overexpressed in various cancers, contributing to tumor survival and resistance to chemotherapy. By targeting MCL-1, BTSA1 helps to restore the natural cell death process in cancer cells, making them more susceptible to treatment. This makes it a valuable tool in the development of novel therapeutic strategies for cancers that are resistant to conventional therapies. Additionally, BTSA1 is used in biochemical assays to study the mechanisms of apoptosis and to screen for potential drug candidates that can effectively modulate this pathway. Its role in these areas underscores its significance in advancing cancer research and improving therapeutic outcomes.